Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CRAVE: Empagliflozin or Ranolazine for Right Ventricular Failure
NCT06570473Phase 2Recruiting
- Sponsor
- University of Alberta
- Start
- Jul 2025
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in pulmonary hypertension (PH), Right ventricular dysfunction (RVD) and right-sided heart failure comparing Empagliflozin, Ranolazine and Standard of Care (3 arms). Primary endpoints: Proportion of eligible participants approached that consent at 16 weeks, Proportion of participants who consent that are randomized at 16 weeks and 3 more. Started Jul 2025; status: recruiting.
02
Drugs
empagliflozinranolazine
03
Conditions
pulmonary hypertension (PH)Right ventricular dysfunction (RVD)right-sided heart failure
Beyond the preview
Go deeper on NCT06570473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06570473.